Key result
Pacemaker implantation successfully controlled refractory torsade de pointes and resolved bradycardia-induced heart failure in a 2-year-old boy with anti-Ro/SSA antibody-associated CAVB.
Why the study?
Anti-Ro/SS-A antibody associated congenital complete atrioventricular block can occasionally occur later than the neonatal period, and anti-Ro/SS-A antibody also contributes to sinus bradycardia or QT prolongation.
Case Report (n=1)
No
Pacemaker management successfully controlled refractory torsade de pointes and improved heart failure in a 2-year-old boy with anti-Ro/SSA antibody-related congenital complete atrioventricular block.
Answers are grounded in this paper and cite their sources.
May support pacemaker-propranolol in refractory pediatric TdP with congenital AV block; hypothesis-generating and requires prospective validation.
Congenital complete atrioventricular block (CAVB) is a rare but life-threatening disease. Most CAVB cases are caused by the transfer of maternal anti-Ro/SS-A antibody to the fetus through the placenta. Anti-Ro/SS-A antibody associated CAVB generally occurs in the neonatal period; however, it may occasionally occur later. Recently, it has been reported that anti-Ro/SS-A antibody contributes not only to CAVB but also to the development of sinus bradycardia or QT prolongation. Here we report an infant case of refractory torsade de pointes (TdP), which was controlled by a pacemaker management. A 2-year-old boy visited our hospital because he suffered from bronchitis. Nebulized beta stimulant, expectorant, and leukotriene receptor antagonist were administered. During the physical examination, we noticed the patient’s bradycardia. We performed an electrocardiogram (ECG) and significant bradycardia and QT prolongation were confirmed (Fig. 1a). A medical history taken from the mother revealed that she was found to be positive for the anti-Ro/SSA antibody and the patient had been noted as having severe bradycardia during fetal period in another institution. We therefore retrieved his previous ECG during his neonatal period and reconfirmed the findings (Fig. 1b). An ECG that was performed immediately after his birth showed no abnormal findings, so he did not receive clinical follow up after the neonatal period. We requested further investigation in the initial institution, but the recorded ECG revealed a normal corrected QT interval (Fig. 1c). Holter ECG was therefore scheduled. Six months after suffering from bronchitis, he was referred to our emergency room because of febrile seizure. An ECG detected TdP (Fig. 1d-1), and magnesium sulfate was infused immediately. Subsequent ECG after elimination of TdP revealed CAVB with an atrial rate of 100 beats/min and ventricular rate of 45 beats/min (Fig. 1d-2). Because the corrected QT interval was markedly prolonged at 560 ms we presumed that convulsions were induced from ventricular fibrillation caused by a prolonged QT interval. Laboratory examination detected increased brain natriuretic peptide levels of 579.9 pg/ mL. Myocardial enzyme analysis excluded myocarditis. A chest X-ray showed cardiomegaly with a cardiothoracic ratio of 58% accompanied by pulmonary congestion. Echocardiography revealed a compressed intraventricular septum at an end-systolic phase without anatomical anomaly. Although TdP responded to magnesium sulfate infusion, it was refractory and repetitive, so a temporary pacemaker implantation for arrhythmia management was performed on the third day of admission. The pulmonary artery pressure measurements during the cardiac catheterization showed systolic pressure of 42, diastolic pressure of 14, and average pressure of 24 mmHg. Calculated pulmonary vascular resistance was 1.93 Wood unit * m and mean pulmonary artery wedge pressure was 14 mmHg. We considered that pulmonary hypertension was caused by bradycardia-induced heart failure. Pacemaker management was initiated with ventricular pacing of 100 beats/ min, and propranolol was introduced. The corrected QT interval was shortened to 465 ms. After the pacemaker management was initiated, magnesium sulfate was able to be discontinued. Brain natriuretic peptide and cardiothoracic ratio were decreased, and a round-shaped intraventricular septum was confirmed on echocardiography. A permanent pacemaker was implanted on the sixth day of hospitalization and VVI pacing with 100 beats/min was started. The TdP disappeared after pacemaker implantation. He was discharged on day 21 after admission. Brain natriuretic peptide levels at discharge were reduced to 41.7 pg/mL and the cardiothoracic ratio on chest X-ray was 52% without pulmonary vascular congestion. We performed cardiac catheterization 6 months after pacemaker implantation. Systolic, diastolic, and mean pulmonary artery pressure was 23, 7, and 14 mmHg respectively. Mean pulmonary arterial wedge pressure was 7 mmHg. Pulmonary *Correspondence: Masanori Mizuno, MD, PhD, Department of Pediatrics, St Marianna University School of Medicine, 216-8511, 2-16-1, Sugao, Miyamae Ku, Kawasaki, Japan. Email: m2.waterfield@marianna-u.ac.jp Received 25 March 2019; revised 9 March 2020; accepted 12 March 2020. doi: 10.1111/ped.14232
No takes yet. Share an insight, caveat, or question.
Mizuno et al. (2020) conducted a case report in Anti-Ro/SSA antibody-related atrioventricular block-induced torsade de pointes (n=1). Pacemaker implantation was evaluated. Pacemaker implantation successfully controlled refractory torsade de pointes and resolved bradycardia-induced heart failure in a 2-year-old boy with anti-Ro/SSA antibody-associated CAVB.
Synapse has enriched 10 related papers. Consider them for comparative context: